Status:
COMPLETED
NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary stud...
Eligibility Criteria
Inclusion
- patients have a diagnosis of schizophrenia, as defined by DSM-IV-TR
- patients' symptoms are controlled with Seroquel SR started up to 1 month before the inclusion
- or patients' symptoms are controlled with other atypical antipsychotic in once daily formulation started up to 1 month before the inclusion
Exclusion
- patients who are treated with Seroquel SR or other antipsychotic more than 1 month
- patients with prescribed antipsychotic combinations
- pregnant women or women who are breast-feeding
- patients who have been treated with antipsychotics in depot formulations for the last two months
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00833456
Start Date
February 1 2009
End Date
November 1 2010
Last Update
October 14 2011
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Begunje na Gorenjskem, Slovenia
2
Research Site
Brezovica pri Ljubljani, Slovenia
3
Research Site
Brežice, Slovenia
4
Research Site
Idrija, Slovenia